Cetirizine Drug Intelligence — PatSnap Eureka
Cetirizine: H1 Antagonist Drug Intelligence
Cetirizine Hydrochloride is an approved small molecule H1 receptor antagonist originated by Johnson & Johnson. First approved in 1991, it covers 11 indications and has generated 12 deals through 2026.
Cetirizine Hydrochloride: Global Drug Profile
Cetirizine Hydrochloride is an approved small molecule originated by Johnson & Johnson, with first approval on 1991-12-31. Its global status is approved, and it remains commercially active through multiple regional organizations including UCB Japan Co. Ltd. and Shandong New Time Pharmaceutical Co. Ltd.
Cetirizine selectively antagonizes the H1 receptor, a G protein-coupled receptor activated by histamine. Blockade of H1 prevents histamine-mediated downstream signaling — including vasodilation, increased vascular permeability, and bronchoconstriction — which are the primary mediators of allergic symptoms.
The drug covers 11 total indications in the database, including approved uses in allergic rhinitis (seasonal), rhinitis, dermatitis, and anaphylaxis. Ophthalmic use via the ZERVIATE formulation (cetirizine ophthalmic solution) is evidenced by deal activity involving Nicox and Ocumension Therapeutics.
Active organizations include Shandong New Time Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., and Ocumension Therapeutics (Suzhou) Co., Ltd. UCB’s portfolio has been progressively divested — to GSK in 2009, M8 in Mexico in 2021, and CBC Group in China for $680M in 2024 — reflecting extraction of value from mature assets.
Cetirizine Competitors on the H1 Target Axis
Ten competitors were retrieved on the same H1 target and allergic disease axis, all small molecules. Approvals span 2001 to 2019, with 6 of 10 being fixed-dose combinations, signaling a market shift toward multi-symptom coverage.
Competitor Drugs by First Approval Year
Most recently approved competitor is Olopatadine HCl / Mometasone Furoate (2019); Levocetirizine, Cetirizine’s direct active-enantiomer successor, was approved in 2001.
↗ Click bars to exploreCetirizine Deal Activity by Year (2009–2026)
Deal volume peaked around 2019–2021 driven by ZERVIATE ophthalmic licensing; the $680M CBC/UCB China acquisition in 2024 represents the largest disclosed transaction.
↗ Click bars to exploreCetirizine Indications: Allergic Rhinitis to Dermatitis
Cetirizine Hydrochloride covers 11 total indications in the PatSnap Eureka database. The explicitly named indications include approved uses in allergic rhinitis, rhinitis, dermatitis, and anaphylaxis, with additional ophthalmic use evidenced by ZERVIATE deal activity.
Allergic Rhinitis (Seasonal)
Seasonal allergic rhinitis is the primary approved indication for Cetirizine Hydrochloride. Cetirizine’s H1 antagonism blocks histamine-mediated vasodilation and increased vascular permeability underlying rhinitis symptoms. This is the foundational indication supporting originator approval by Johnson & Johnson in 1991.
Allergy / ImmunologyDermatitis
Dermatitis is an approved indication for Cetirizine Hydrochloride, reflecting the drug’s broad anti-histaminic coverage across IgE-mediated skin conditions. Cetirizine’s blockade of H1 receptors reduces pruritus and inflammatory skin responses associated with dermatitis. This indication is among the 11 listed in the PatSnap Eureka database.
DermatologyAnaphylaxis
Anaphylaxis is listed as an approved or research-stage indication for Cetirizine Hydrochloride in the database. Cetirizine’s H1 receptor blockade addresses histamine-driven components of anaphylactic responses. Its role is as an adjunctive antihistamine in IgE-mediated hypersensitivity conditions.
Allergy / Emergency MedicineAllergic Conjunctivitis (ZERVIATE)
Ophthalmic use of Cetirizine via the ZERVIATE (cetirizine ophthalmic solution) formulation is evidenced by 7 of 12 deals in the dataset, spanning US, China, South Korea, and Gulf markets. Nicox originated the ZERVIATE thread via acquisition of Aciex Therapeutics in 2014, licensing to Eyevance for the US and Ocumension Therapeutics for China ($19.25M). This represents the primary life-cycle extension strategy for the post-patent oral drug.
OphthalmologyOrganizations in the Cetirizine Drug Ecosystem
Johnson & Johnson originated Cetirizine and retains an active manufacturing process patent. UCB has progressively divested its portfolio to GSK, M8 Pharmaceuticals, and CBC Group ($680M, 2024), while Nicox and Ocumension Therapeutics lead the ophthalmic commercialization thread globally.
Top Patent Assignees by Filing Count — Cetirizine
↗ Click bars to exploreJohnson & Johnson
Johnson & Johnson originated Cetirizine Hydrochloride and received first approval in 1991. Johnson & Johnson Consumer Inc holds the only confirmed active manufacturing process patent (CA2734691C, filed 2009) in the retrieved dataset. Johnson & Johnson Vision Care Inc holds an additional active patent in the ophthalmic space.
United StatesUCB
UCB served as a major branded regional marketer of Cetirizine and has progressively divested its portfolio. UCB sold emerging-market rights to GSK in 2009, entered a CNS & Respiratory partnership with M8 Pharmaceuticals in Mexico in 2021, and in 2024 divested its China mature portfolio to CBC Group for $680M.
Belgium / GlobalStrategic Outlook for Cetirizine Assets
Despite patent expiry, Cetirizine’s deal trajectory from 2009 to 2026 signals sustained commercial relevance driven by ophthalmic reformulation and geographic portfolio arbitrage, particularly in China and emerging markets.
Ophthalmic Reformulation as the Primary Value Creation Vector
The ZERVIATE (cetirizine ophthalmic solution) thread has generated 7 of 12 deals in the dataset across US, China, South Korea, and Gulf markets, indicating a viable life-cycle extension strategy for a post-patent oral drug. Nicox originated this thread via acquisition of Aciex Therapeutics in 2014 and subsequently built a global licensing network. BD teams evaluating mature antihistamine assets should treat ophthalmic reformulation as the clearest near-term value pathway.
China as the Highest-Stakes Commercial Battleground
The $680M CBC Group acquisition of UCB’s China mature portfolio in 2024 and the $19.25M Nicox/Ocumension China license confirm China as the most active deal geography for Cetirizine-related assets. BD teams should monitor CBC Group’s portfolio strategy for further sub-licensing or divestiture activity. The concentration of high-value transactions in China reflects both market scale and the premium on branded generics in that market.
Cetirizine vs Levocetirizine Hydrochloride
Click any row to explore further in PatSnap Eureka.
| Dimension | Cetirizine Hydrochloride | Levocetirizine Hydrochloride |
|---|---|---|
| Drug Type | Small molecule | Small molecule |
| Primary Target | H1 receptor | H1 receptor |
| Mechanism of Action | H1 receptor antagonist | H1 receptor antagonist (active R-enantiomer of Cetirizine) |
| Global Status | Approved | Approved |
| First Approved | 1991-12-31 | 2001-08-16 |
| Key Indications | Allergic rhinitis, rhinitis, dermatitis, anaphylaxis; ophthalmic use (ZERVIATE) | H1 target / allergic disease axis; direct successor to Cetirizine |
| Originator | Johnson & Johnson | Not specified in CONTENT |
| Active Organizations | Shandong New Time Pharmaceutical; UCB Japan Co. Ltd.; Ocumension Therapeutics (Suzhou) | Competitor on same H1 target axis; approved approx. 10 years after Cetirizine |
Frequently Asked Questions: Cetirizine Hydrochloride
Cetirizine Hydrochloride is an approved small molecule H1 receptor antagonist. It works by selectively antagonizing the H1 receptor, a G protein-coupled receptor activated by histamine. Blockade of H1 prevents histamine-mediated downstream signaling including vasodilation, increased vascular permeability, and bronchoconstriction, which are the primary mediators of allergic symptoms.
Cetirizine Hydrochloride has 11 total indications in the PatSnap Eureka database. Explicitly named approved indications include seasonal allergic rhinitis, rhinitis, dermatitis, and anaphylaxis. Ophthalmic use for allergic conjunctivitis via the ZERVIATE (cetirizine ophthalmic solution) formulation is also evidenced by deal activity involving Nicox and Ocumension Therapeutics.
Cetirizine Hydrochloride was originated by Johnson & Johnson, with first approval in 1991. Active organizations in the database today include Shandong New Time Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., and Ocumension Therapeutics (Suzhou) Co., Ltd. CBC Group acquired UCB’s China mature portfolio for $680M in 2024.
Ten competitors were retrieved on the same H1 target and allergic disease axis, all small molecules, with approvals spanning 2001 to 2019. The most direct competitors are Levocetirizine Hydrochloride (active R-enantiomer of Cetirizine, approved 2001) and Bilastine (second-generation non-sedating antihistamine, approved 2010). Six of the ten retrieved competitors are fixed-dose combinations, including Olopatadine HCl / Mometasone Furoate (approved 2019) and Azelastine HCl / Fluticasone Propionate (approved 2012).
12 deals were retrieved spanning 2009 to 2026. The largest disclosed transaction was CBC Group’s $680M acquisition of UCB’s China mature portfolio in August 2024. The Nicox/Ocumension ZERVIATE China license was valued at $19.25M (2019). Other notable deals include Nicox licensing ZERVIATE to Eyevance for the US (2017), Hikma co-promoting ZERVIATE in the US with Eyevance (2021), and GSK acquiring UCB products in emerging markets (2009).
10 patents were retrieved in the dataset, with the IP landscape predominantly expired, consistent with a drug first approved in 1991. Only 1 patent is confirmed active among the retrieved patents: CA2734691C (method for making cetirizine tablets, filed 2009, assigned to Johnson & Johnson Consumer Inc). Two additional active patents appear in the assignee table — held by Johnson & Johnson Vision Care Inc and Haleon US Holdings LLC — but are not detailed in the 10 retrieved records.
Data and insights on this page are based on a limited patent, clinical, and biopharma intelligence dataset and are for reference only. Figures may not represent the complete drug development landscape.